Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2008-01-24
2010-08-17
Puttlitz, Karl J (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S194000, C564S200000, C564S202000, C564S211000
Reexamination Certificate
active
07776919
ABSTRACT:
This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, β-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.
REFERENCES:
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4356108 (1982-10-01), Schwab et al.
patent: 4873313 (1989-10-01), Crawford et al.
patent: 5153226 (1992-10-01), Chucholowski et al.
patent: 5202424 (1993-04-01), Vlassara et al.
patent: 5585344 (1996-12-01), Vlassara et al.
patent: 5688653 (1997-11-01), Ulrich et al.
patent: 5795907 (1998-08-01), Kalindjian et al.
patent: 5864018 (1999-01-01), Morser et al.
patent: 5922770 (1999-07-01), Peschke et al.
patent: 5939526 (1999-08-01), Gaugler et al.
patent: 6100098 (2000-08-01), Newkirk
patent: 6613801 (2003-09-01), Mjalli et al.
patent: 6677299 (2004-01-01), Stern et al.
patent: 6825164 (2004-11-01), Stern et al.
patent: 7067554 (2006-06-01), Mjalli et al.
patent: 2004/0097407 (2004-05-01), Mjalli et al.
patent: 2005/0026811 (2005-02-01), Mjalli et al.
patent: 2379695 (2001-12-01), None
patent: 1176918 (1958-12-01), None
patent: 2 005 674 (1979-04-01), None
patent: 7-51550 (1995-06-01), None
patent: WO 95/09838 (1995-04-01), None
patent: WO 96/32385 (1996-10-01), None
patent: WO 97/22618 (1997-06-01), None
patent: WO 97/26913 (1997-07-01), None
patent: WO 97/39121 (1997-10-01), None
patent: WO 97/39125 (1997-10-01), None
patent: WO 95/35279 (1997-12-01), None
patent: WO 98/22138 (1998-05-01), None
patent: WO 98/33492 (1998-08-01), None
patent: WO 99/07402 (1999-02-01), None
patent: WO 99/18987 (1999-04-01), None
patent: WO 99/25690 (1999-05-01), None
patent: WO 99/50230 (1999-10-01), None
patent: WO 99/54485 (1999-10-01), None
patent: WO 00/20458 (2000-04-01), None
patent: WO 00/20621 (2000-04-01), None
patent: WO 01/12598 (2001-02-01), None
patent: WO 01/92210 (2001-12-01), None
Albercio et al., “Coupling Reagents and Activation” Methods in Enzymology 289:104-126, Academic Press, San Diego (1997).
Barton et al., “In Protection of N-H Bonds and NR3” Protective Groups in Organic Chemistry, J.F.W. McOmie, ED, Plenum Press, New York, NY (1973).
Berge et al., “Pharmaceutical Salts” Journal of Pharmaceutical Sciences, vol. 66, pp. 1-19, (1977).
Chitaley et al., “Antagonism of Rho-Kinase Stimulates Rate Penile Erection via a Nitric Oxide-Independent Pathway” Nature Medicine, vol. 44, pp. 119-122, (2002).
Database CAPLUS on STN (Columbus OH, USA) No. 112:199010 Abstract of Pirkle et al., “Separation of the enantiomers of N-protected α-amino acids as anilide and 3, 5-dimethylanilide derivatives” (1990).
Database CAPLUS on STN (Columbus OH, USA) No. 116:58986 Abstract of Hamada et al., Preparation of anilide derivatives for determination of enzymes (1992).
Database CAPLUS on STN (Columbus OH, USA) No. 122:106460 Abstract of Sivanandaiah et al., “Synthesis of peptides mediated by KOBI” (1995).
Database CAPLUS an STN (Columbus OH, USA) No. 131:267043 Abstract of Tsukita et al., “Aminocarboxylic acids, selectin inhibitors containing them, and their uses” (1999).
Database CAPLUS on STN (Columbus OH, USA) No. 92:41660 Abstract of Frappier et al., “Peptidic Alkaloids, X. Approach for the Synthesis of Peptidic Alkaloids. 1. Reactivity of N-toylsulfonylaziridines towards reactive nucleophiles” (1978).
Database CAPLUS on STN (Columbus OH, USA) No. 105:60932 Abstract of Digenis at al., “Peptidyl Carbamates Incorporating Amino Acid Isosteres as Novel Elastase Inhibitors” (1986).
Database CAPLUS on STN (Columbus OH, USA) No. 114:228476 Abstract for Vidubiriene et al., “Synthesis and study of derivatives of 3-alkylamino)-2-(methylthio)carbaxylla acids” (1990).
Database CAPLUS on STN (Columbus, OH, USA No. 92:41524 Abstract of Dobrev, et al. “Addition of N.N-disubstituted amides to N-benzoyl diphenyl kelimine in the presence of lithium amide in liquid ammonia” (1978).
Degenhardt et al., “Chemical Modification of Proteins by Methylglyoxal” Cellular and Molecular Biology, vol. 44, pp. 1139-1145, (1998).
Digenis et al., “Peptidyl Carbamates Incorporating Amino Acid Isosteres as Novel Elastase inhibitors” Journal of Medicinal Chemistry, vol. 29, pp. 1468-1476, (1986).
Dyer et al., “Accumulation of Maillard Reaction Products in Skin Collagen in Diabetes and Aging” Journal of Clinical Investigation, vol., 91, pp. 2463-2369, (1993).
Dyer et al., “Formation of Pentosidine during NonenzymatIc Browning of Proteins by Glucose” Journal of Biological Chemistry, vol., 266, pp. 11654-11660 (1990).
Frappier et al., “Peptidic Alkaloids. X. Approach for the Synthesis of Peptidic Alkaloids. 1. Reactivity of N-toylsulfonylazirldlnes towards reactive nucleophiles” Tetrahedron, vol. 34, pp. 2911-2916, (1978) (Language—French).
Greene et al., “Protection for Amino Group” Protective Groups in Organic Synthesis, John Wiley and Sons, New York, NY, Chapter 7 (1981).
Hammes, et al., “Diabetic Retinopathy Risk Correlates with Intracellular Concentrations of the Glycoxidatlon product N°-(Carboxymethyl) Ly7sine Independently of Glycohaemoglobin Concentrations” Diabetologia, vol. 42, pp. 603-607, (1999).
Hoffman et al., “RAGE Mediates a Novel Prainflammatory Axis: A Central Cell Surface Receptor for S100/Calgranulin Polypeptides” Cell, vol., 97, pp. 889-901, (1999).
Horl et al., “The Receptor for Advanced Glycation End Products (RAGE) is a Cellular Binding Site for Amphoterin” Journal of Biological Chemistry, vol., 270, pp. 25752-25761, (1995).
Huttunen et al., “Receptor for Advanced Glycation End Products (RAGE)-Mediated Neurite Outgrowth and Activation of NF-Kappa B Require the Cytoplasmic Domain of the Receptor But Different Downstream Signaling Pathways” Journal of Biological Chemistry, vol., 274, pp. 19919-19924 , (1999).
International Search Report for PCT application PCT/US02/06707 dated Nov. 5, 2002.
International Search Report for related PCT application, PCT/US01/17251 dated Aug. 14, 2001.
Kumar et al, “RAGE at the Blood-Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloidβ1-40Petptide” Neuroscience Program, 141-#255.19 (2000).
Leder et al., “v-HA-ras Transgene Abrogates the Initiation Step in Mouse Skin Tumorigenesis: Effects of Phorbol Esters and Retinoic Acid” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, pp. 9178-9182, (1990).
Li et al., “Characterization and Functional Analysis of the Promoter for RAGE, the Receptor for Advanced Glycation End Products” Journal of Biological Chemistry, vol., 272, pp. 16496-16506, (1997).
Li et al., “Sp1-Binding Elements in the Promoter of RAG Are Essential for Amphoterin-Mediated Gene Expression in Cultured Neuroblastoma Cells.” Journal of Biological Chemistry, vol. 272, pp. 16498-16506, (1997).
Lugering et al., “The Myeloic Related Protein MRP8/14 (27E10 Antigen)—Usefulness as a Potential Marker for Disease Activity in Ulcerative Colitis and Putative Biological Function” European Journal of Clinical Investigation, vol. 25, pp. 659-664 (1995).
Miyata et al., “Beta2—Micro globulin Mod
Andrews Robert C.
Gopalaswamy Ramesh
Mjalli Adnan M. M.
Wysong Christopher L.
Kilpatrick & Stockton LLP
Puttlitz Karl J
TransTech Pharm, Inc.
LandOfFree
Carboxamide derivatives as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carboxamide derivatives as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboxamide derivatives as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149891